SCHEMBL3397941

SCHEMBL3397941

CCOC(=O)c1sc(Cl)nc1-c1nc2ccccc2s1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.51
KDM4E B2RXH2 4/20 0.51
MAPT P10636 3/20 0.51
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
TP53 P04637 1/20 0.51
ALOX12 P18054 1/20 0.51
STAT3 P40763 1/20 0.51
SMN1; SMN2 Q16637 4/20 0.48
RAB9A P51151 3/20 0.48
NPC1 O15118 2/20 0.48
CDC7 O00311 3/20 0.47
DBF4 Q9UBU7 3/20 0.47
HSD17B10 Q99714 2/20 0.47
GAA P10253 2/20 0.47
HPGD P15428 2/20 0.46
MAPK1 P28482 1/20 0.46
LMNA P02545 1/20 0.46
TRPM8 Q7Z2W7 1/20 0.45
DHODH Q02127 3/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3401356 0.86 ALDH1A1 (0.66) ALDH1A1KDM4EMAPTMEN1KMT2A
SCHEMBL3893108 0.80 ALDH1A1 (0.71) ALDH1A1KDM4EMEN1KMT2ACDC7
SCHEMBL3403482 0.78 LMNA (0.62) ALDH1A1KDM4EMEN1KMT2ARAB9A
SCHEMBL11279731 0.78 CDC7 (0.69) ALDH1A1KDM4EMAPTMEN1KMT2A
SCHEMBL694406 0.75 NPSR1 (0.66) ALDH1A1KDM4EMAPTMEN1KMT2A
SCHEMBL4298781 0.75 RARA (0.64) ALDH1A1KDM4EMAPTMEN1KMT2A
SCHEMBL11159408 0.75 MAPT (0.62) ALDH1A1KDM4EMAPTMEN1KMT2A
SCHEMBL1505433 0.75 LMNA (0.48) ALDH1A1MAPTMEN1KMT2ACDC7
SCHEMBL211598 0.74 ALDH1A1 (0.69) ALDH1A1KDM4EMAPTMEN1KMT2A
SCHEMBL2492109 0.73 TRPM8 (0.65) ALDH1A1KDM4EMAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2158199-B1 PIPERIDINE COMPOUNDS AND USES THEREOF ASTRAZENECA AB (SE) 2010-11-17 EP disclosed
EP-2158199-B1 PIPERIDINE COMPOUNDS AND USES THEREOF ASTRAZENECA AB (SE) 2010-11-17 EP disclosed
WO-2008152418-A1 PIPERIDINE COMPOUNDS AND USES THEREOF ASTRAZENECA AB (SE) 2008-12-18 WO disclosed
US-20080312255-A1 PIPERDINE COMPOUNDS AND USES THEREOF-911 ASTRAZENECA AB (SE) 2008-12-18 US disclosed
US-20080312255-A1 PIPERDINE COMPOUNDS AND USES THEREOF-911 ASTRAZENECA AB (SE) 2008-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312255-A1 PIPERDINE COMPOUNDS AND USES THEREOF-911 NISCH, PIR, QDPR ALDH1A1 243/4885KDM4E 3497/4885MAPT 2837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.